EP2769712A1 — Pharmaceutical formulation comprising DPP-IV inhibitor agglomerates and DPP-IV inhibitor particles
Assigned to Siegfried International AG · Expires 2014-08-27 · 12y expired
What this patent protects
The invention relates to a pharmaceutical formulation comprising DPP-IV inhibitor agglomerates and DPP-IV inhibitor particles, wherein the DPP-IV inhibitor is in free form or in form of a salt thereof, wherein at least 45 wt.% of the DPP-IV inhibitor particles and DPP-IV inhibito…
USPTO Abstract
The invention relates to a pharmaceutical formulation comprising DPP-IV inhibitor agglomerates and DPP-IV inhibitor particles, wherein the DPP-IV inhibitor is in free form or in form of a salt thereof, wherein at least 45 wt.% of the DPP-IV inhibitor particles and DPP-IV inhibitor agglomerates have a size when measured using sieve analysis of more than 250 µm. The pharmaceutical formulation shows improved stability and allows easy production of solid oral dosage forms due to the good flow properties of the particles and agglomerates.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.